News

bit.bio will use Automata to automate a key aspect of its production of iPSC derived human cells

Further products in CNS portfolio aim to address the translation gap and accelerate research and drug discovery for neurodegenerat...

New advisors will provide important and independent guidance.

Products aim to address the translation gap and accelerate research and drug discovery for neurodegenerative disease.

The award was presented at evening ceremony in central London.

The posters demonstrate the capability of opti-ox technology to create any human cell.

bit.bio wins biotech of the year for the second time and CEO of the year for Mark Kotter.

The new Huntington’s disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.